Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

21.4%

6 terminated/withdrawn out of 28 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

9 of 18 completed trials have results

Key Signals

1 recruiting9 with results6 terminated

Enrollment Performance

Analytics

Phase 1
21(75.0%)
Phase 2
7(25.0%)
28Total
Phase 1(21)
Phase 2(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (28)

Showing 20 of 28 trials
NCT04598009Phase 2Recruiting

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

Role: collaborator

NCT03971409Phase 2Active Not Recruiting

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Role: collaborator

NCT03170206Phase 1Completed

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Role: collaborator

NCT04074967Phase 1Active Not Recruiting

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

Role: collaborator

NCT03231306Phase 2Completed

Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas

Role: collaborator

NCT04375527Phase 2Terminated

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Role: collaborator

NCT03374254Phase 1Completed

Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)

Role: collaborator

NCT01921335Phase 1Completed

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

Role: collaborator

NCT03843775Phase 1Completed

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Role: collaborator

NCT01894672Phase 2Completed

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Role: collaborator

NCT02834364Phase 2Completed

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

Role: collaborator

NCT01859026Phase 1Completed

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Role: collaborator

NCT04005144Phase 1Terminated

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Role: collaborator

NCT02384083Phase 1Completed

Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients

Role: collaborator

NCT02510001Phase 1Completed

MEK and MET Inhibition in Colorectal Cancer

Role: collaborator

NCT03158103Phase 1Completed

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Role: collaborator

NCT02089230Phase 1Terminated

MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

Role: collaborator

NCT04292119Phase 1Unknown

Lorlatinib Combinations in Lung Cancer

Role: collaborator

NCT01828034Phase 1Completed

First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma

Role: collaborator

NCT00650572Phase 1Completed

A Study of ARRY-380 in Patients With Advanced HER2+ Cancer

Role: collaborator